D'Elia RV - Search Results

1

Targeting the "cytokine storm" for therapeutic benefit.

D'Elia RV, Harrison K, Oyston PC, Lukaszewski RA, Clark GC. D'Elia RV, et al. Clin Vaccine Immunol. 2013 Mar;20(3):319-27. doi: 10.1128/CVI.00636-12. Epub 2013 Jan 2. Clin Vaccine Immunol. 2013. PMID: 23283640 Free PMC article. Review.

2

Protection against experimental melioidosis following immunization with live Burkholderia thailandensis expressing a manno-heptose capsule.

Scott AE, Laws TR, D'Elia RV, Stokes MG, Nandi T, Williamson ED, Tan P, Prior JL, Atkins TP. Scott AE, et al. Clin Vaccine Immunol. 2013 Jul;20(7):1041-7. doi: 10.1128/CVI.00113-13. Epub 2013 May 15. Clin Vaccine Immunol. 2013. PMID: 23677322 Free PMC article.

3

Differential role for interleukin-6 during Francisella tularensis infection with virulent and vaccine strains.

Laws TR, Clark G, D'Elia RV. Laws TR, et al. Infect Immun. 2013 Aug;81(8):3055-6. doi: 10.1128/IAI.00234-13. Epub 2013 May 28. Infect Immun. 2013. PMID: 23716611 Free PMC article. No abstract available.

4

Targeting the "Rising DAMP" during a Francisella tularensis Infection.

D'Elia RV, Laws TR, Carter A, Lukaszewski R, Clark GC. D'Elia RV, et al. Antimicrob Agents Chemother. 2013 Sep;57(9):4222-4228. doi: 10.1128/AAC.01885-12. Epub 2013 Jun 24. Antimicrob Agents Chemother. 2013. PMID: 23796927 Free PMC article.

5

Delayed presence of alternatively activated macrophages during a Francisella tularensis infection.

D'Elia RV, Laws TR, Núñez A, Taylor C, Clark GC. D'Elia RV, et al. Microb Pathog. 2015 Jan;78:37-42. doi: 10.1016/j.micpath.2014.10.002. Epub 2014 Oct 2. Microb Pathog. 2015. PMID: 25284816

6

"FoxP3 Hunting" during infection with Francisella tularensis.

D'Elia RV, Laws TR, Núñez A, Clark GC. D'Elia RV, et al. Int J Immunopathol Pharmacol. 2014 Oct-Dec;27(4):585-95. doi: 10.1177/039463201402700414. Int J Immunopathol Pharmacol. 2014. PMID: 25572738 Free article.

7

Immune profiling of the progression of a BALB/c mouse aerosol infection by Burkholderia pseudomallei and the therapeutic implications of targeting HMGB1.

Laws TR, Clark GC, D'Elia RV. Laws TR, et al. Int J Infect Dis. 2015 Nov;40:1-8. doi: 10.1016/j.ijid.2015.09.003. Epub 2015 Sep 7. Int J Infect Dis. 2015. PMID: 26358857 Free article.

8

Mitogen-activated protein kinases (MAPKs) are modulated during Francisella tularensis infection, but inhibition of extracellular-signal-regulated kinases (ERKs) is of limited therapeutic benefit.

Saint RJ, D'Elia RV, Bryant C, Clark GC, Atkins HS. Saint RJ, et al. Eur J Clin Microbiol Infect Dis. 2016 Dec;35(12):2015-2024. doi: 10.1007/s10096-016-2754-1. Epub 2016 Oct 6. Eur J Clin Microbiol Infect Dis. 2016. PMID: 27714591 Free PMC article.

9

Current and future developments in the treatment of virus-induced hypercytokinemia.

Wong JP, Viswanathan S, Wang M, Sun LQ, Clark GC, D'Elia RV. Wong JP, et al. Among authors: d elia rv. Future Med Chem. 2017 Feb;9(2):169-178. doi: 10.4155/fmc-2016-0181. Epub 2017 Jan 27. Future Med Chem. 2017. PMID: 28128003 Free PMC article. Review.

10

Mitogen-activated protein kinases (MAPKs) are modulated during in vitro and in vivo infection with the intracellular bacterium Burkholderia pseudomallei.

D'Elia RV, Saint RJ, Newstead SL, Clark GC, Atkins HS. D'Elia RV, et al. Eur J Clin Microbiol Infect Dis. 2017 Nov;36(11):2147-2154. doi: 10.1007/s10096-017-3038-0. Epub 2017 Aug 30. Eur J Clin Microbiol Infect Dis. 2017. PMID: 28856457 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

27 results

Search Page

Filters